Actively Recruiting
Study of Low-Dose Colchicine and Ticagrelor to Prevent Major Vascular Events After Ischemic Stroke Due to Atherosclerosis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-08
2800
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of low-dose colchicine and ticagrelor to reduce the risk of major vascular events in patients who have had an ischemic stroke due to atherosclerosis. This study tests whether adding colchicine 0.5 mgday to standard medical care can lower the risk of problems like stroke and heart attack over 36 to 60 months. It also compares ticagrelor 90 mg twice daily with aspirin to see which better reduces long-term vascular risks in these patients. Participants are randomly assigned to one of four groups combining colchicine or no colchicine with ticagrelor or aspirin. Treatment lasts from 36 to 60 months. The study is designed to observe differences in vascular event rates among these groups. Colchicine is studied for its anti-inflammatory effects, while ticagrelor and aspirin are antiplatelet medications that affect blood clotting. During the study, participants will undergo regular check-ups and monitoring for events such as ischemic stroke, myocardial infarction, and vascular death. The primary outcomes focus on occurrences of these events over 36 months. Secondary outcomes include recurrent strokes, coronary events, and revascularization procedures. Safety and adherence will be monitored throughout the treatment period, which may last up to five years.
CONDITIONS
Brief Title
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Research Team
P
Pierre Amarenco, Pr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here